ReviewCurrent oncology reports2008
The biology and management of uveal melanoma.
Review in Current oncology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.Journal of vascular and interventional radiology : JVIR · 2015Trial
- Laparoscopic distal pancreatectomy for metastatic melanoma originating from the choroidal membrane: a case report.Surgical case reports · 2021Article
- Review
- Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.Cancers · 2020Review
- Article
- Adjuvant Ipilimumab in High-Risk Uveal Melanoma.Cancers · 2019Article
- Reprogramming Cells for Synergistic Combination Therapy with Nanotherapeutics against Uveal Melanoma.Biomimetics (Basel, Switzerland) · 2018Article
- Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.Molecules (Basel, Switzerland) · 2018Article
- Review
- Targeted silencing of the ADP-ribosyltransferase 3 gene inhibits the migration ability of melanoma cells.Oncology letters · 2018Article
- Evaluation ofOncoTargets and therapy · 2017Article
- Uveal melanoma: epidemiology, etiology, and treatment of primary disease.Clinical ophthalmology (Auckland, N.Z.) · 2017Review
- Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p.PloS one · 2017Article
- Immunotherapy for uveal melanoma.Melanoma management · 2016Review
- Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140.American journal of translational research · 2016Article
- Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.The American journal of pathology · 2016Article
- MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression.PloS one · 2015Article
- Uveal melanoma: evaluation of extrascleral extension using thin-section MR of the eye with surface coils.La Radiologia medica · 2014Article
- Latest developments in the biology and management of uveal melanoma.Current oncology reports · 2013Review
- Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma.Clinical & experimental metastasis · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma is the most common primary intraocular malignancy in adults. Overall mortality rate remains high because of the frequent development of metastatic disease, especially hepatic metastasis. While traditional systemic chemotherapies provide only marginal benefit to patients, local treatments for hepatic metastases, such as immunoembolization, have improved patient prognoses. Progress has also been made in identifying potential targets in the pathways involved in apoptosis, proliferation, invasion, metastasis, and angiogenesis of uveal melanoma. Among these pathways, the c-Kit, c-Met, and IGF-1R signal pathways and the PTEN-related PI3K-Akt pathway are the most important targets. Clinical trials using blockades of these pathways in conjunction with strategies to facilitate apoptosis is a direction for future clinical trials. Application of these approaches in the adjuvant setting after primary therapy for high-risk uveal melanoma patients is also a future consideration to improve the clinical outcome of this disease.
Indexed as
Identifiers
18706273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.